Shire Pharmaceuticals: A culture of excellence

Amid a spate of merger and acquisition activity in the life sciences space, in March 2018 came the news that Japan-based Takeda was considering plans to acquire biopharma company Shire.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

The curtain closes on three major drug disputes

11 February 2026 Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.

Big Pharma

The clinical trial dilemma: Navigating European practice

27 November 2025 Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.

Big Pharma

Report reveals surge of AI adoption in IP but lawyers remain cautious

20 November 2025 A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.

More features

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling

Eli Lilly escapes $278m payout in biotech licensing dispute

Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices

Wiggin’s new litigation partner deepens ‘technically complex’ offer

Mintz gains ex-Winston & Strawn partner and ITC expert

Generic rival blocked as AZ defends diabetes stronghold

The curtain closes on three major drug disputes

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’

Shire Pharmaceuticals: A culture of excellence

More on this story

Editor's picks

Editor's picks

More features